Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium

European Journal of Pharmacology

Volumn 476, Issue 1-2, 2003, Pages 97-105

  Bundkirchen, Andreas ^a   Nguyen, Quang ^a   Brixius, Klara ^a   Bölck, Birgit ^a   Mehlhorn, Uwe ^a   Schwinger, Robert H G ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Contractility; Enantiomer; Human; Metabolite; Myocardium; Nebivolol

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CALCIUM ION; DRUG METABOLITE; FORSKOLIN; ISOPRENALINE; METOPROLOL; NEBIVOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG METABOLISM; ENANTIOMER; FEMALE; HEART CONTRACTION; HUMAN; HUMAN TISSUE; HYDROXYLATION; IN VIVO STUDY; MALE; MUSCLE FIBRIL; MUSCLE FORCE; PRIORITY JOURNAL; SERUM; SINGLE DRUG DOSE;

EID: 0142138775     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02116-2     Document Type: Article

References (34)

1. Bristow M.R., Ginsburg R., Minobe W., Cubicciotti R.S., Sageman W.S., Lurie K., Billingham M.E., Harrison D.C., Stinson E.B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in the failing human hearts. N. Engl. J. Med. 307:1982;205-211.
2. 2+ sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J. Pharmacol. Exp. Ther. 295:2000;1284-1290.
3. Brixius K., Bundkirchen A., Bölck B., Mehlhorn U., Schwinger R.H. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br. J. Pharmacol. 133:2001;1330-1338.
4. Broeders M.A., Doevendans P.A., Bekkers B.C., Bronsaer R., Van Gorsel E., Heemskerk J.W., Egbrink M.G., Van Breda E., Reneman R.S., Van Der Zee R. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation. 102:2000;677-684.
5. 2+ sensitivity. Eur. J. Pharmacol. 422:2001;175-180.
6. 1-adrenoceptors in human myocardium. J. Pharmacol. Exp. Ther. 300:2002;794-801.
7. 125I]iodocyanopindolol binding studies. Eur. J. Pharmacol. 460:2003;16-26.
8. Cockcroft J.R., Chowienczyk P.J., Brett S.E., Chen C.P., Dupont A.G., Van Nueten L., Wooding S.J., Ritter J.M. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther. 274:1995;1067-1071.
9. De Crée J., Cobo C., Geukens H., Verhaegen H. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol. Angiology. 41:1990;95-105.
10. De Crée J., Van Nueten L., Geukens H., Verhaegen H. Comparative cardiac hemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in healthy volunteers. Int. J. Clin. Pharmacol. Res. 12:1992;159-163.
11. Flesh M., Maack C., Cremers B., Bäumer A.T., Südkamp M., Böhm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation. 100:1999;346-353.
12. Gao Y., Nagao T., Bond R.A., Janssens W.J., Vanhoutte P.M. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J. Cardiovasc. Pharmacol. 17:1991;964-969.
13. Goldstein M., Vincent J.L., De Smet J.M., Barvais L., Van Nueten L., Scheijgrond H., d'Hollander A., Leclerc J.L., Kahn R.J. Administration of nebivolol after coronary artery bypass in patients with altered left ventricular function. J. Cardiovasc. Pharmacol. 22:1993;253-258.
14. Himmelmann A., Hedner T., Snoeck E., Lundgren B., Hedner J. Haemodynamic effects and pharmacokinetics of oral D- and L-nebivolol in hypertensive patients. Eur. J. Clin. Pharmacol. 51:1996;259-264.
15. Janssens W.J., Van de Water A., Xhonneux R., Reneman R.S., Van Nueten J.M., Janssen P.A.J. Nebivolol is devoid of intrinsic sympathomimetic activity. Eur. J. Pharmacol. 159:1989;89-95.
16. Janssen P.M., Zeitz O., Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: protective effects of nebivolol. Eur. J. Pharmacol. 366:1999;223-232.
17. Jasper R.J., Michel M.C., Insel P.A. Molecular mechanism of β-adrenergic receptor blockers with intrinsic sympathomimetic activity. FASEB J. 2:1988;2891-2894.
18. 2-receptor antagonists cimetidine and ranitidine. Br. J. Clin. Pharmacol. 43:1997;201-204.
19. Kojda G., Kottenberg G. Regulation of basal myocardial function by NO. Cardiovasc. Res. 41:1999;514-523.
20. Paulus W.J., Frantz S., Kelly R.A. Nitric oxide and cardiac contractility in human heart failure. Time for reappraisal. Circulation. 104:2001;2260-2262.
21. Pauwels P.J., Gommeren W., Van Lommen G., Janssen P.A.J., Leysen J.E. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various β-adrenergic blockers. Mol. Pharmacol. 34:1988;843-851.
22. Sanchez R.A. Effects of nebivolol on left ventricular function in patients with essential hypertension. Drug Investig. 3(Suppl. 1):1991;155-160.
23. Schmidt U., Schwinger R.H., Böhm M. Interaction of halothane with inhibitory G-proteins in the human myocardium. Anesthesiology. 83:1995;353-360.
24. Schwinger R.H., Böhm M., Erdmann E. Evidence against spare or uncoupled beta-adrenoceptors in the human heart. Am. Heart J. 119:1990;899-904.
25. Schwinger R.H., Böhm M., Pieske B., Erdmann E. Different β-adrenoceptor-effector coupling in human ventricular and atrial myocardium. Eur. J. Clin. Pharmacol. 21:1991;443-451.
26. Schwinger R.H., Böhm M., Koch A., Uhlmann R., Überfuhr P., Kreuzer E., Reichert B., Erdmann E. Force frequency-relationship in human atrial and ventricular myocardium. Mol. Cell. Biochem. 119:1993;73-78.
27. Schwinger R.H., Böhm M., Koch A., Schmidt U., Morano I., Eissler H.J., Überfuhr P., Reichert B., Erdmann E. The failing human heart is unable to use the Frank-Starling mechanism. Circ. Res. 74:1994;959-969.
28. Shah A.M., MacCarthy P.A. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol. Ther. 86:2000;49-86.
29. Van de Water A., Janssens W., Van Neuten J., Xhonneux R., De Cree J., Verhaegen H., Reneman R.S., Janssen P.A. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J. Cardiovasc. Pharmacol. 11:1988;552-563.
30. Van Neuten L., De Crée J. Nebivolol: comparison of the effects of DL-nebivolol, D-nebivolol, L-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc. Drugs Ther. 12:1998;339-344.
31. 14C-Nebivolol. Nebivolol-Documentation.
32. Varma D.R., Shen H., Deng X.F., Peri K.G., Chemtob S., Mulay S. Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br. J. Pharmacol. 127:1999;895-902.
33. Wisenbaugh T., Katz I., Davis J., Essop R., Skoularigis J., Middlemost S., Rothlisberger C., Skudicky D., Sareli P. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J. Am. Coll. Cardiol. 21:1993;1094-1100.
34. Xhonneux R., Wouters L., Reneman R.S., Janssen P.A.J. The L-enantiomer of nebivolol potentiates the blood pressure lowering effect of the D-enantiomer. Eur. J. Pharmacol. 181:1990;261-265.